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Abstract 47 
Objective 48 
Recently, computed tomography arthrography (CTa) was introduced as 49 
quantitative imaging biomarker to estimate cartilage sulphated glycosaminoglycan 50 
(sGAG) content in human cadaveric knees. Our aim was to assess the correlation 51 
between in vivo CTa in human osteoarthritis (OA) knees and ex vivo reference 52 
standards for sGAG and collagen content.  53 
Design 54 
In this prospective observational study 11 knee OA patients underwent CTa 55 
before total knee replacement (TKR). Cartilage X-ray attenuation was determined in 6 56 
cartilage regions. Femoral and tibial cartilage specimens harvested during TKR were 57 
re-scanned using equilibrium partitioning of an ionic contrast agent with micro-CT 58 
(EPIC-μCT), which served as reference standard for sGAG. Next, cartilage sGAG and 59 
collagen content were determined using dimethylmethylene blue (DMMB) and 60 
hydroxyproline assays. The correlation between CTa X-ray attenuation, EPIC-μCT X-61 
ray attenuation, sGAG content and collagen content was assessed. 62 
Results 63 
CTa X-ray attenuation correlated well with EPIC-μCT (r=0.76, 95% 64 
credibility interval (95%CI) 0.64 to 0.85). CTa correlated moderately with the 65 
DMMB assay (sGAG content) (r=-0.66, 95%CI -0.87 to -0.49) and to lesser extent 66 
with the hydroxyproline assay (collagen content) (r=-0.56, 95%CI -0.70 to -0.36). 67 
Conclusions 68 
Outcomes of in vivo CTa in human OA knees correlate well with sGAG 69 
content. Outcomes of CTa also slightly correlate with cartilage collagen content. 70 
Since outcomes of CTa are mainly sGAG dependent and despite the fact that further 71 
  4 
validation using hyaline cartilage of other joints with different biochemical 72 
composition should be conducted, CTa may be suitable as quantitative imaging 73 
biomarker to estimate cartilage sGAG content in future clinical OA research. 74 
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Introduction 83 
Knee osteoarthritis (OA) is the most common joint disease in middle-aged and 84 
elderly, causing serious morbidity and large socio-economic impact 
(1, 2)
. Since no 85 
definitive treatment options other than joint replacement surgery in end stage OA are 86 
available, research focuses on development of disease modifying osteoarthritis drugs 87 
(DMOADs) which may be effective in early OA, for example by improving cartilage 88 
biochemical composition 
(3, 4)
.  89 
To non-invasively monitor effectiveness of these novel interventions on 90 
cartilage biochemical composition, imaging techniques are essential. Therefore, 91 
quantitative imaging assessing important cartilage composites i.e. sulphated 92 
glycosaminoglycan (sGAG) and collagen, became of interest 
(5)
. 93 
Most imaging techniques applied in clinical research are magnetic resonance 94 
imaging (MRI) based, e.g. delayed gadolinium-enhanced MRI of cartilage 95 
(dGEMRIC) for analyzing sGAG content 
(6)
 and T2-mapping for analyzing collagen 96 
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content 
(7)
. Computed tomography (CT) based techniques have also been developed, 97 
but are mainly applied in in vitro or animal research. Examples are: equilibrium 98 
partitioning of an ionic contrast agent using micro-CT (EPIC-μCT) and μCT 99 
arthrography to estimate sGAG content 
(8-14)
.     100 
Recently, a clinically applicable protocol for CT arthrography (CTa) was 101 
introduced as a potential alternative technique to MRI based estimate of cartilage 102 
biochemical composition 
(15)
. Outcomes of ex vivo CTa applied in human cadaveric 103 
knee joints were shown to strongly correlate with cartilage sGAG content based on 104 
the inverse relation between the negatively charged sGAG and the ionic contrast agent 105 
used, similar to the working mechanism of dGEMRIC. 
(15)
. However, outcomes of 106 
CTa were also dependent on integrity of the collagen network of cartilage, which 107 
influences the speed of contrast influx into cartilage 
(15)
. Although CTa was already 108 
applied in vivo by comparing its outcomes to dGEMRIC and cartilage morphology 109 
observed during arthroscopy 
(16, 17)
, these studies did not assess the correlation 110 
between CTa and reference standards for cartilage biochemical composition and were 111 
not performed in knee OA patients which constitute an important target population for 112 
quantitative imaging techniques for cartilage composition.  113 
The aim of this study was to assess the correlation between in vivo CTa in 114 
human knees with OA and ex vivo reference standards for sGAG and collagen 115 
content. 116 
 117 
Methods 118 
Study design and participants 119 
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For this prospective observational study, conducted between October 2012 and 120 
December 2013, all consecutive patients scheduled for total knee replacement (TKR) 121 
at our institution were approached. 122 
The inclusion criteria were: age ≥ 18 years and radiographic knee OA with 123 
asymmetric distribution and a maximum of grade 1-2 (doubtful or definite osteophyte 124 
formation without definite joint space narrowing) according to the Kellgren & 125 
Lawrence (KL) grading system 
(18)
 in the least affected tibiofemoral compartment. We 126 
chose to include only these patients to be sure that we captured a relatively wide range 127 
of cartilage quality and therefore also sGAG content of the articular cartilage. 128 
Exclusion criteria were: glomerular filtration rate < 60 ml/min, previous reactions to 129 
CT contrast agent and co-morbidities in the ipsilateral lower extremity precluding 130 
exercise after contrast administration. 131 
 We performed a power analysis in which we used the Fisher transformation 132 
(19)
 to assess the number of measurements needed to establish a correlation coefficient 133 
of at least 0.7 (considered a good correlation 
(20)
) with a predefined 95% confidence 134 
interval width of 0.5 - 0.9, and found that 25 measurements would be needed. Since 135 
six measurements are performed per participant, three participants would be enough 136 
for our study. Because we considered this number very low, we decided to include at 137 
least 10 participants (60 measurements for the correlation analyses) until the end date 138 
of the study (December 2013). 139 
The study was approved by the institutional review board of our institution 140 
(MEC-2012-218) and written informed consent was obtained from all participants. 141 
 142 
Acquisition of CT arthrography 143 
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CTa was performed four weeks before TKR. This time window was chosen to 144 
allow detection of infection caused by the intra-articular injection well before surgery. 145 
Patients were positioned in a supine position and after disinfection, 15 ml 30% 146 
ioxaglate (Hexabrix 320, Mallinckrodt, Hazelwood, USA) and 70% 1% phosphate 147 
buffered saline (PBS) solution was injected intra-articularly using a 21 gauge needle 148 
(15)
 and a superolateral approach 
(21)
. We first aspirated synovial fluid from the knee in 149 
order to confirm that the needle was positioned in the knee joint and to ensure that we 150 
could inject the 15 ml of contrast dilution while minimizing further dilution due to 151 
extensive joint effusion. To promote contrast distribution throughout the joint, 152 
participants actively exercised their knee for two minutes over the full possible range 153 
of motion immediately after the injection.  154 
Ten minutes post-injection, CT in the axial plane was acquired using a dual-155 
source multidetector spiral CT scanner (SOMATOM Definition Flash, Siemens 156 
Healthcare AG, Germany). We used a tube voltage of 80 kV, units of current of 3140 157 
mAs, pitch of 0.35 and collimation of 32 x 0.6 mm 
(15)
. Scan time was approximately 158 
30 seconds. These parameters resulted in an effective radiation dose of 0.4 millisievert 159 
(mSv) and an effective skin dose of 120 milligray (mGy) which is well below the 160 
threshold of 1000 mGy above which deterministic effects on the skin are expected 
(22)
. 161 
All scans were reconstructed in the sagittal plane with an effective slice 162 
thickness of 0.75 mm and a sharp reconstruction kernel. Multiplanar reconstruction 163 
was performed resulting in an image voxel size of 0.265 by 0.265 mm, e.g. an in-164 
plane resolution of 512 x 512 voxels.  165 
 166 
Analysis of CT arthrography 167 
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Reconstructed datasets were segmented into binary datasets using a local 168 
attenuation threshold algorithm (3D-Calc, Skyscan, Kontich, Belgium) (Figure 1A-D) 169 
(10, 23)
. These binary datasets (Figure 1C-D) were used to manually draw six cartilage 170 
regions of interest (ROIs): posterior non-weight-bearing femoral cartilage (pFC) 171 
(Figure 1E), weight-bearing femoral cartilage (wbFC) (Figure 1F) and weight-172 
bearing tibial cartilage (wbTP) of the medial and lateral tibiofemoral compartment 173 
(Figure 1G). Each ROI consisted of 40 contiguous slices and was manually drawn by 174 
a researcher with four years of experience in musculoskeletal imaging (JvT) using CT 175 
Analyser software (Skyscan, Kontich, Belgium). In each ROI, mean cartilage X-ray 176 
attenuation was calculated using CT Analyser.  177 
 178 
Harvesting of cartilage and acquisition of EPIC-μCT  179 
During TKR, weight-bearing and non-weight-bearing femoral cartilage and 180 
weight-bearing tibial cartilage with adjacent subchondral bone were harvested, stored 181 
in saline and transported directly to the laboratory.  182 
We used EPIC-μCT as reference standard for cartilage sGAG content since its 183 
outcomes have a good correlation with cartilage sGAG content 
(8, 9, 14)
. Similar to CTa, 184 
EPIC-μCT provides information on sGAG distribution of cartilage within the entire 185 
cartilage volume, allowing analysis of articular cartilage regions exactly matching the 186 
cartilage ROIs analyzed with CTa.  187 
Between 30 minutes and 1 hour after surgery, all specimens were removed 188 
from the saline and incubated in ioxaglate solution for 24 hours at room temperature 189 
(24-26)
. A 20% ioxaglate with 80% PBS 1% solution was used since this results in 190 
optimal cartilage segmentation at the air/cartilage and bone/cartilage interfaces 
(15)
. 191 
The contrast solution also contained Ethylenediaminetetraacetic acid (EDTA) (Sigma 192 
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Aldrich, St Louis, USA) and protease inhibitors (Roche, Basel, Switzerland) to 193 
prevent sGAG removal from the specimen during incubation.  194 
EPIC-μCT was performed using a Skyscan 1076 (Skyscan, Kontich, Belgium) 195 
with the following scan settings: isotropic voxel size of 35 μm; voltage of 95 kV; 196 
current of 100 mA; field of view 68 mm with a 1.0 mm aluminum / 0.25 mm copper 197 
filter over 198
o
 with a 0.36 degree rotation step. Plastic foil was wrapped around the 198 
specimen to avoid dehydration during scanning. Depending on the size of the 199 
specimen, scan time was 0.5 – 1.5 hours. The datasets were reconstructed identically 200 
using NRecon software (Skyscan, Kontich, Belgium).  201 
 202 
Analysis of EPIC-μCT 203 
To enable comparison of corresponding cartilage regions, EPIC-μCT datasets 204 
were registered to CTa datasets with Multimodality Image Registration using 205 
Information Theory (MIRIT, University of Leuven) 
(27)
. This automated registration 206 
algorithm uses a rigid transformation model (translations and rotations) and uses 207 
mutual information as a similarity measure for the registration of the μCT datasets to 208 
the CT datasets. Next, using CT Analyser software, datasets were segmented into 209 
binary datasets using a previously determined fixed attenuation threshold (25 gray 210 
values for air and 120 gray values for subchondral bone) 
(15)
. In the segmented μCT 211 
datasets, cartilage ROIs corresponding with ROIs of CTa were drawn and mean X-ray 212 
attenuation was calculated.  213 
 214 
Biochemical cartilage analyses 215 
After acquisition of EPIC-μCT, four (posterior femoral cartilage), six or eight 216 
(weight-bearing femoral and plateau cartilage based on the size) full thickness 217 
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cartilage explants of 6 mm diameter were taken using a biopsy punch from 218 
standardized locations corresponding with cartilage of the ROIs analyzed with CTa 219 
and EPIC-μCT. Location and number of cartilage explants were chosen to ensure 220 
representative cartilage samples in each ROI. 221 
Since ioxaglate used for EPIC-μCT might interact with biochemical assays 222 
(pilot tests, data not shown), explants were washed at room temperature for 24 hours 223 
in 1% PBS. During washing, EDTA and protease inhibitors were added to prevent 224 
sGAG loss from cartilage. Next, explants were cut in halves and stored separately in 225 
airtight tubes at -20 °C together with the washing solution.  226 
Before biochemical analyses were performed, explants were thawed at room 227 
temperature. One half of each explant was digested in papain solution containing 250 228 
µg/ml papain and 5 MM l-cytein HCl overnight at 60 ºC. sGAG content in cartilage 229 
and in the washing solution of the matching explant was quantified with the 230 
1,9dimethylmethylene blue (DMMB) dye binding assay at pH 3 described by 231 
Farndale et al. 
(28)
. Absorption ratios at 540nm and 595 nm were used to calculate 232 
sGAG content using chondroitin sulphate (Sigma Aldrich, St Louis, USA) as 233 
standard. Total sGAG content in explant and washing solution was calculated to 234 
correct for possible loss of sGAG during washing.  235 
The other half of each explant was used to quantify collagen content based on 236 
the hydroxyproline content according to Bank et al. 
(29)
. Samples were digested with 237 
alpha-chymotrypsin followed by a papain solution and digests were hydrolyzed with 238 
equal volumes 12M HCl at 95 ºC overnight. Samples were then dried and re-dissolved 239 
in water. Hydroxyproline content was measured using a colorimetric method with 240 
chloramine-T and dimethylaminobenzaldehyde as reagents and hydroxyproline as 241 
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standerd (Merck, Darmstadt, Germany) at extinction 570 nm. Values of degraded and 242 
intact collagen content were summed, resulting in total collagen content per explant.  243 
Next, for each ROI four to eight explants were used to calculate the mean 244 
sGAG and collagen content by averaging the content of the explants taken from that 245 
specific ROI. The mean sGAG and the mean collagen content of a specific cartilage 246 
ROI could then be correlated with the mean CT and μCT attenuation in the matching 247 
ROI. 248 
 249 
Statistical analysis 250 
To assess the correlation between CTa and reference tests (EPIC-μCT, sGAG 251 
content and collagen content), a four-dimensional multivariate mixed-effects model 252 
was applied. In this model, it is assumed that the CTa and the reference tests are 253 
multivariately normally distributed (i.e. Y~N4(μ,Σ), where Y = (CTa, EPIC-μCT, 254 
sGAG content, collagen content); μ and Σ are the mean vector (i.e. μ = (μ1 = CTa, μ2 = 255 
EPIC-μCT, μ3 = sGAG content, μ4 = collagen content)) and covariance matrix of these 256 
variables, respectively. To take into account potential intrinsic correlation between 257 
outcomes of different ROIs within one participant, a random intercept was included in 258 
the model (e.g. μ1,i.j. = β1 + b1,I ; i = 1, … , 11, j; j= 1, …, 62).  259 
Pearson’s correlation coefficients of CTa and each reference test were 260 
extracted from the results of this model. For each Pearson’s correlation coefficient the 261 
95% credibility interval (95%CI) was calculated. To assess goodness-of-fit, we used 262 
an omnibus posterior predictive check (PPC) 
(30)
. We computed a Bayesian p-value 263 
with extreme values of this p-value (e.g., < 0:05 or > 0:95) indicating a poor fit of the 264 
model to the data 
(30)
.  265 
  12 
To assess if the correlation coefficients calculated within the model were 266 
significantly different, we calculated the contour probability of the correlations. For 267 
these values, similar to the Bayesian p-value, extreme values, i.e. <0.05 or >0.95, 268 
indicate that there is a statistically significant difference between two correlation 269 
coefficients 
(31)
.   270 
An additional univariate mixed-effects regression analysis was performed to 271 
estimate the capability of in vivo CTa to predict outcomes of ex vivo EPIC-μCT (thus 272 
sGAG content). In this analysis, we modeled EPIC-μCT outcomes based on CTa 273 
measurements, using random effects to capture heterogeneity between patients, and 274 
predicted the EPIC-μCT outcomes and their 95%CI for all cartilage regions. 275 
All analyses were performed using a Bayesian approach with Markov chain 276 
Monte Carlo (McMC) sampling using WinBugs 
(32)
. 277 
 278 
Results 279 
Participants 280 
Fourteen patients were included. Two participants were excluded because their 281 
TKR was postponed after inclusion, in one participant ioxaglate was injected extra-282 
articularly and four cartilage specimens (two weight-bearing cartilage specimens of 283 
the medial tibial plateau, one posterior non-weight-bearing cartilage specimen of the 284 
lateral femoral condyle and one weight-bearing cartilage specimen of the medial 285 
femoral condyle) were severely damaged during surgery and were therefore excluded 286 
from the analysis. Therefore, results are based on data of 11 participants (5 women 287 
and 6 men, 7 left and 4 right knees).  288 
The mean age with standard deviation was 64 ± 7 years and their mean body 289 
mass index with standard deviation was 33 ± 6 kg/m
2
. The KL grades in the medial 290 
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tibiofemoral compartments were 3 or 4 in seven participants and 1 or 2 in four 291 
participants. KL grades in the lateral tibiofemoral compartments were 1 or 2 in nine 292 
participants and 3 in two participants. We did not observe any adverse reactions 293 
related to the intra-articular contrast injections. 294 
 295 
Correlation of CTa, EPIC-µCT and biochemical cartilage analyses 296 
For the applied four-dimensional mixed-effects model, the Bayesian p-value of 297 
the PPC was 0.52, which indicates that the model assumptions appear to be satisfied.  298 
Mean CTa X-ray attenuation in all femoral and tibial cartilage ROIs correlated 299 
well with attenuation of EPIC-μCT (r=0.76, 95%CI 0.64 to 0.85; Figure 2A). When 300 
each ROI was analyzed separately, the range of correlation coefficients between 301 
outcomes of CTa and EPIC-μCT was 0.75 to 0.80.  302 
The correlation between CTa and sGAG content measured using the DMMB 303 
assay was moderate (r=-0.66, 95%CI -0.87 to -0.49; Figure 2B). A range of -0.75 to -304 
0.60 was observed for the correlation coefficients between X-ray attenuation of CTa 305 
and sGAG content in all separate cartilage ROIs.  306 
The correlation between outcomes of CTa and collagen content measured 307 
using the hydroxyproline assay was also moderate (r=-0.56, 95%CI -0.70 to -0.36; 308 
Figure 2C). Here, a range of correlation coefficients from -0.56 to -0.51 was obtained 309 
for each separate ROI. 310 
Mean EPIC-μCT outcomes and sGAG content measured using the DMMB 311 
assay correlated well (r=-0.81, 95%CI -0.87 to -0.69; Figure 2D). The range of 312 
correlation coefficients for each separate ROI was -0.82 to -0.75. 313 
By calculating the p-values of the contour probability of the different 314 
correlations we observed that the correlation between CTa and EPIC-μCT was 315 
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significantly different from the correlation between CTa and sGAG or collagen 316 
content (contour probability > 0.99). The correlation between EPIC-μCT and sGAG 317 
content was significantly different from the correlation between EPIC-μCT and 318 
collagen content (contour probability = 0.002). The other correlation coefficients did 319 
not differ significantly from each other. 320 
The matched images of CTa, EPIC-μCT and histology (visual representation 321 
of sGAG content using Safranin-O staining) representing cartilage with relatively 322 
high and low sGAG content shown in Figure 3 confirmed the good correlation 323 
between CTa and EPIC-μCT and cartilage sGAG content. 324 
 The additional univariate mixed-effects regression analysis to estimate the 325 
capability of CTa to predict EPIC-μCT showed that the 95%CIs of the predicted 326 
EPIC-μCT outcomes overlap with all of the observed outcomes of CTa, indicating 327 
good predictive performance (Figure 4). 328 
 329 
Discussion 330 
Quantitative imaging biomarkers that non-invasively estimate cartilage 331 
biochemical composition are essential for development and monitoring of DMOADs in 332 
OA. This study was performed to assess the correlation between in vivo CTa in human 333 
OA knees and ex vivo reference standards for sGAG and collagen content.  334 
Our results show a good correlation between X-ray attenuation of CTa and EPIC-335 
μCT, a good predictive performance of CTa for EPIC-μCT outcomes, and a somewhat 336 
less pronounced correlation between CTa and cartilage sGAG content determined by 337 
the DMMB assay. These results are in agreement with previous research showing a 338 
good correlation between outcomes of CTa acquired in ex vivo human cadaveric knee 339 
joints and EPIC-μCT (15). The results are also consistent with several previous in vitro 340 
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studies examining the correlation between contrast-enhanced (micro)CT and the 341 
sGAG content of articular cartilage 
(8, 9, 14)
. Therefore, we believe that CTa X-ray 342 
attenuation may be used as a quantitative estimate for sGAG content of articular 343 
cartilage in future clinical OA research.  344 
The difference in strength of correlation between CTa and sGAG content 345 
measured using EPIC-μCT versus DMMB assay might be caused by the fact that the 346 
attenuation of EPIC-μCT and cartilage sGAG content are well correlated, but not by a 347 
linear relationship. This indicates that, although not fully specific, EPIC-μCT is good 348 
reference test for cartilage sGAG content. Another explanation for the difference in 349 
strength of correlation may be that the ROIs in CTa and EPIC-μCT were matched 350 
exactly by image registration while the DMMB assay was limited to assessment of 351 
sGAG content in representative cartilage explants that did not correspond exactly with 352 
the cartilage volume of the imaging ROIs. We chose this approach since we 353 
considered it to be reliable to analyze representative focal cartilage explants taken 354 
from standardized locations out of the cartilage ROIs analyzed using CTa and EPIC-355 
μCT. Since there were no large spatial differences in sGAG distribution within 356 
cartilage ROIs in EPIC-μCT (data not shown), we are convinced that this did not 357 
influence our results compared to analyzing total cartilage ROIs using the DMMB 358 
assay.  359 
An import remark with regard to the interpretation our results is the fact that 360 
the observed good correlation between CTa and EPIC-μCT does not automatically 361 
imply that both tests have equal or comparable diagnostic capacity. Calculation of 362 
diagnostic performance statistics such as sensitivity, specificity, positive predictive 363 
value and negative predictive value requires the availability of threshold values that 364 
are indicative for disease (in our study OA). Although sGAG content is diminished in 365 
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OA, no threshold values exist for sGAG content in relation to diagnosis of OA. 366 
Despite the absence of these analyses, but because of the moderate to strong 367 
correlation between outcomes of CTa and cartilage sGAG content and the good 368 
predictive performance of CTa for EPIC-μCT (thus sGAG) outcomes, we consider 369 
CTa as a worthwhile quantitative estimator of cartilage sGAG content in future 370 
clinical research. 371 
We found a moderate correlation between outcomes of CTa and collagen 372 
content of cartilage measured using the hydroxyproline assay. This result could 373 
potentially be explained by a strong relation between collagen and sGAG content of 374 
cartilage and a concomitant loss of sGAG and collagen in the OA process. Cartilage 375 
sGAG and collagen content were, however, only weakly correlated in our study 376 
(r=0.40, data not shown). This indicates that, in addition to sGAG content, the 377 
integrity of the collagen network also influences contrast influx into cartilage as 378 
suggested in previous ex vivo research 
(15)
. It is important to note that in CTa, there is 379 
no equilibrium between cartilage sGAG content and the contrast agent because CTa 380 
images are acquired already 10 minutes after contrast administration. This is unlike 381 
EPIC-μCT in which cartilage is incubated in contrast agent for 24 hours (8, 9, 14). 382 
Therefore, measurements from non-equilibrium CTa are also influenced by other 383 
factors than sGAG content alone 
(24-26)
. In particular, the collagen network of the 384 
extracellular matrix of the cartilage, which determines the permeability of the 385 
cartilage, influences the diffusion rate of contrast agent into the cartilage besides its 386 
sGAG content 
(33, 34)
. Contrast diffusion goes slowly in healthy cartilage, in which an 387 
intact collagen network and densely packed collagen parallel to the cartilage surface 388 
result a relative low permeability of the cartilage 
(35, 36)
. When the collagen network is 389 
impaired, e.g. in case of loss of collagen content, cartilage permeability increases, 390 
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resulting in higher diffusion rate of contrast into the cartilage. The influence of 391 
collagen content of cartilage on CTa outcomes, however, is less pronounced 392 
compared to the influence of cartilage sGAG content since the correlations were 393 
significantly different. This suggests that, although not totally sGAG specific, CTa 394 
may be considered a useful imaging biomarker to estimate cartilage sGAG content in 395 
future human OA research.  396 
CTa might be a worthwhile quantitative biochemical cartilage imaging 397 
technique in future clinical research additional to contrast-enhanced MRI based 398 
techniques used for the same purpose. CTa has a relatively fast acquisition time and 399 
can be acquired already ten minutes after contrast administration, while the delay 400 
between intravenous contrast administration in knee dGEMRIC is at least 1.5 hours 401 
(37)
. This makes CTa more patient friendly and clinically feasible than MRI. 402 
Moreover, in the generally middle-aged or elderly OA population, the relative long 403 
acquisition time of MRI compared to CT (minutes versus seconds) and the number of 404 
patients with possible contra-indication for MRI (for example non MRI compatible 405 
implants) may favor CTa as an alternative to MRI in clinical OA research 
(38)
. CTa 406 
might also be applicable as imaging biomarker for cartilage biochemical composition 407 
in large cohort studies since it is relatively cheap and widely available 
(39)
.  408 
Potential limitations of CTa include concerns of ionizing radiation. The 409 
effective radiation dose used for CTa as presented in this paper (0.4 mSv) is four times 410 
higher than a regular CT of the knee  
(40)
. However, it has been shown that CTa acquired 411 
using only 10% of this dose also has a good correlation with cartilage sGAG content ex 412 
vivo in cadaveric knees 
(41)
.  Besides, active knee flexion and extension may be 413 
impossible for the full range of motion for OA patients, resulting in variations in contrast 414 
concentration across the knee joint. Recent research by Silvast et al., however, shows that 415 
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differences in contrast concentration do not influence the speed of contrast influx into 416 
cartilage and would therefore not influence the reliability of CTa outcomes 
(42)
. Finally, 417 
although not observed in our study and also not reported in other studies applying 418 
CTa in vivo in humans 
(16, 17)
, the intra-articular injection introduces the risk of 419 
infection and increases the risk of knee pain after injection. It may be worthwhile to 420 
perform fluoroscopic-guided intra-articular injections in future research with CTa 421 
since this may overcome the problem of extra-articular contrast agent deposition, 422 
which happened in one of our study participants, however against increased costs and 423 
logistic complexity of the procedure.  424 
 Based on our results and despite the potential drawbacks we propose that CTa 425 
may be applicable in future clinical OA research as an estimate for cartilage sGAG 426 
content in cross-sectional study designs. Of course, more research is needed, particularly 427 
to assess reproducibility in OA patients before CTa could be applied in longitudinal 428 
studies. Such a reproducibility study might also benefit from including more participants 429 
and different delays between contrast administration and CT acquisition to assess if this 430 
influences the correlation between CTa and cartilage composition in full thickness ROIs. 431 
In addition, a depth-wise analysis to assess the effect of different concentrations of 432 
cartilage composites throughout the extracellular matrix and across the cartilage layer 433 
would be interesting, possibly include patellar cartilage, which is thicker and has been 434 
shown to have a different composition than femoral and tibial cartilage 
(43)
. Further 435 
studies will also need to be performed to assess the capability of CTa to serve as a 436 
predictive tool, for example for OA progression or clinical OA symptoms. Also, assessing 437 
the capability of CTa to estimate cartilage sGAG and collagen content in fibrocartilage or 438 
cartilage of other joints could be of interest to assess the influence of the differences in 439 
cartilage composition on the diffusion of contrast agent into the cartilage. Nowadays, OA 440 
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is considered a whole joint disease in which not only cartilage, but also subchondral bone, 441 
menisci and synovium play important roles in disease development and progression 
(44)
. 442 
The simultaneous analysis of cartilage and subchondral bone was also described 443 
previously in in vitro studies using contrast-enhanced μCT (45, 46). It would also be 444 
worthwhile to assess the ability of CTa to evaluate cartilage and meniscus composition 445 
within one examination. Simultaneous analysis of cartilage and meniscus composition has 446 
recently been described for contrast-enhanced MRI 
(47, 48)
 and contrast-enhanced CT in 447 
vitro 
(49, 50)
. Finally, future research might assess the possibility of injecting the contrast 448 
agent intravenously instead of intra-articularly to make the technique more patient 449 
friendly. This dGEMRIC like approach will, however, be challenging because the 450 
intra-articular contrast is also used for the purpose of cartilage segmentation. 451 
Moreover, an intravenous approach requires a longer delay between contrast 452 
administration and acquisition of the CT scan. 453 
In conclusion, our study shows that when applied in vivo in human OA knees, 454 
X-ray attenuation of CTa correlates well with sGAG content. Outcomes of CTa also 455 
slightly correlate with cartilage collagen content. Since outcomes of CTa are mainly 456 
sGAG dependent and despite the fact that further validation using hyaline cartilage of 457 
other joint with different biochemical composition should be conducted, CTa may be 458 
suitable as quantitative imaging biomarker to estimate cartilage sGAG content in 459 
future clinical OA research. 460 
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Figure Legends 647 
Figure 1: Regions of interest in CTa and EPIC-μCT datasets 648 
Representative sagittally reconstructed images of a medial and lateral compartment of 649 
a knee joint which underwent CTa (A-B). After segmentation into a binary datasets, 650 
the different regions of interest are shown in 2D (C-D) and in a 3D representation: the 651 
posterior non-weight-bearing cartilage of the femoral condyles (pFC) (E), the weight-652 
bearing cartilage of the femoral condyles (wbFC) (F) and the weight-bearing cartilage 653 
of the tibial plateaus (wbTP) (G). After image registration, the same ROIs were 654 
analyzed in EPIC-μCT datasets. 655 
   656 
Figure 2: Correlation plots of CTa, EPIC-μCT and ex vivo reference standards for 657 
sGAG and collagen content of articular cartilage 658 
Correlation plots of mean attenuation of CTa in all anatomical ROIs with EPIC-μCT 659 
attenuation (A), sGAG content of the cartilage measured with DMMB assay (B), 660 
collagen content of the cartilage measured with hydroxyproline assay (C) and  mean 661 
  28 
attenuation of EPIC-μCT and sGAG content measured with DMMB assay (D).  The 662 
dashed lines indicate the 95% credibility interval of the Pearson’s correlation 663 
coefficient. 664 
 665 
Figure 3: Cartilage sGAG content estimated using CTa, EPIC-μCT and histology  666 
Representative images of matching sagittal slides of CTa, EPIC-μCT and histology 667 
(Appendix 1, which is available online, provides the methods used for preparation and 668 
staining of the bone-cartilage specimen with safranin-O). The attenuation of cartilage 669 
is visualized in color: A high attenuation represents a low sGAG content of cartilage 670 
and a low attenuation represents a high sGAG content. A high intensity of safranin-O 671 
staining on histology represents a high sGAG content and a low intensity or 672 
discoloration represents a low or absent sGAG content. The top row shows visual 673 
agreement in high cartilage sGAG content and the bottom row shows visual 674 
agreement for low cartilage sGAG content. 675 
 676 
Figure 4: Capability of in vivo CTa to predict outcomes of ex vivo EPIC-μCT. 677 
Filled circles are observed outcomes of EPIC-μCT and the non-filled circles are 678 
predicted EPIC-μCT outcomes based on CTa outcomes. It is clearly visible that the 679 
95%CI of the predicted EPIC-μCT outcomes overlap with all of the observed 680 
outcomes of CTa, which indicates that CTa is able to predict outcomes of EPIC-μCT 681 
and therefore cartilage sGAG content.  682 
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